Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

476 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Maertens JA, Rahav G, Lee DG, Ponce-de-León A, Ramírez Sánchez IC, Klimko N, Sonet A, Haider S, Diego Vélez J, Raad I, Koh LP, Karthaus M, Zhou J, Ben-Ami R, Motyl MR, Han S, Grandhi A, Waskin H; study investigators. Maertens JA, et al. Among authors: raad i. Lancet. 2021 Feb 6;397(10273):499-509. doi: 10.1016/S0140-6736(21)00219-1. Lancet. 2021. PMID: 33549194 Clinical Trial.
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group. Maertens J, et al. Among authors: raad i. Clin Infect Dis. 2004 Dec 1;39(11):1563-71. doi: 10.1086/423381. Epub 2004 Nov 9. Clin Infect Dis. 2004. PMID: 15578352 Clinical Trial.
Posaconazole: a broad-spectrum triazole antifungal.
Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Torres HA, et al. Among authors: raad ii. Lancet Infect Dis. 2005 Dec;5(12):775-85. doi: 10.1016/S1473-3099(05)70297-8. Lancet Infect Dis. 2005. PMID: 16310149 Review.
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, Negroni R, Perfect JR, Pitisuttithum P, Restrepo A, Schiller G, Pedicone L, Ullmann AJ. Raad II, et al. Clin Infect Dis. 2006 Jun 15;42(12):1726-34. doi: 10.1086/504328. Epub 2006 May 8. Clin Infect Dis. 2006. PMID: 16705579 Clinical Trial.
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. Walsh TJ, et al. Among authors: raad i. Clin Infect Dis. 2007 Jan 1;44(1):2-12. doi: 10.1086/508774. Epub 2006 Nov 28. Clin Infect Dis. 2007. PMID: 17143808 Clinical Trial.
Phaeohyphomycosis in a tertiary care cancer center.
Ben-Ami R, Lewis RE, Raad II, Kontoyiannis DP. Ben-Ami R, et al. Among authors: raad ii. Clin Infect Dis. 2009 Apr 15;48(8):1033-41. doi: 10.1086/597400. Clin Infect Dis. 2009. PMID: 19267655
476 results